COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study.


Journal

Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 15 10 2021
accepted: 13 12 2021
pubmed: 20 1 2022
medline: 22 11 2022
entrez: 19 1 2022
Statut: ppublish

Résumé

People with cancer are at higher risk of serious illness and death from COVID-19 infection. We investigated COVID-19 vaccine uptake among patients with solid organ and blood cancers and explored factors related to hesitancy. Cross-sectional online survey of adults with a history of cancer at three health services across metropolitan and regional Victoria. Vaccine hesitancy was measured by the validated Oxford COVID-19 vaccine hesitancy scale. There were 1073 respondents: 56% female; median age 62 years (range 23 - 91). Commonest tumor types included breast 29%, gastrointestinal 19%, hematological 15%, genitourinary 15%, and lung 8%. Thirty-six percent had metastatic disease, and 54% were receiving active anticancer treatment. Eighty-four percent of respondents indicated positive intent toward COVID-19 vaccination, 10% were undecided, and 6% indicated negative attitudes. At least one vaccine dose had been received by 65% of respondents, leaving 35% unvaccinated. Fifty-eight percent of unvaccinated patients answered that they would "definitely" or "probably" take a vaccine. Higher vaccine uptake was significantly associated with older age, male gender, English as first language, longer time since cancer diagnosis, and not being on current anticancer treatment. Concerns regarding vaccine side effects, particularly thrombosis, and the desire for clear medical advice were prominent among unvaccinated respondents. Despite being eligible for COVID-19 vaccination since March 2021, a substantial minority of patients with cancer remained unvaccinated as of August 2021. Targeted communication and educational resources addressing vaccine safety in the context of cancer are key to promoting vaccine uptake in this vulnerable population.

Identifiants

pubmed: 35043559
doi: 10.1111/ajco.13754
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-577

Informations de copyright

© 2022 John Wiley & Sons Australia, Ltd.

Références

Tsamakis K, Gavriatopoulou M, Schizas D, et al. Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (review). Oncol Lett. 2020;20(1):441-447.
Powis M, Milley-Daigle C, Hack S, et al. Impact of the early phase of the COVID pandemic on cancer treatment delivery and the quality of cancer care: a scoping review and conceptual model. Int J Qual Health Care. 2021;33(2):1-12.
Czeisler MÉ, Kennedy JL, Wiley JF, et al. Delay or avoidance of routine, urgent and emergency medical care due to concerns about COVID-19 in a region with low COVID-19 prevalence. Respirology. 2021;26(7):707-712.
Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. J Clin Oncol. 2020;43(6):452-455.
Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428-455.
Australian Government, Department of Health. Priority groups for COVID-19 vaccination program: phase 1b. https://www.health.gov.au/sites/default/files/documents/2021/03/priority-groups-for-covid-19-vaccination-program-phase-1b_1.pdf. Accessed 25 August 2021.
Australian Government, Department of Health. COVID-19 vaccination rollout update -2 August 2021. https://www.health.gov.au/sites/default/files/documents/2021/08/covid-19-vaccine-rollout-update-2-august-2021.pdf. Accessed 25 August 2021.
Prinsloo S. Melbourne Institute. Survey of the impact of COVID-19 in Australia. https://melbourneinstitute.unimelb.edu.au/publications/research-insights/ttpn/wave-34. Accessed 25 August 2021.
Australian Government, Department of Prime Minister and Cabinet. National plan to transition Australia's national COVID-19 response. https://www.pm.gov.au/sites/default/files/media/national-plan-to-transition-australias-national-covid-19-response-30-july-2021.pdf. Accessed 25 August 2021.
MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161-4164.
Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021;9(2):160.
Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225-228.
Kaplan RM, Milstein A. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA. 2021;118(10):e2021726118.
Villarreal-Garza C, Vaca-Cartagena BF, Becerril-Gaitan A, et al. Attitudes and factors associated with COVID-19 vaccine hesitancy among patients with breast cancer. JAMA Oncol. 2021;7(8):1242-1244.
Kreps S, Dasgupta N, Brownstein JS, et al. Public attitudes toward COVID-19 vaccination: the role of vaccine attributes, incentives, and misinformation. npj Vaccines. 2021;6(1):73.
Dizon DS, Hoffman KD, Gentile D, et al. People with cancer are likely to accept the COVID-19 vaccine, but politics tracks with attitudes: an inspire and COSMO survey. J Clin Oncol. 2021;39(15_suppl):1531-1531.
Brodziak A, Sigorski D, Osmola M, et al. Attitudes of patients with cancer towards vaccinations-results of online survey with special focus on the vaccination against COVID-19. Vaccines. 2021;9(5):411.
Di Noia V, Renna D, Barberi V, et al. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey. Eur J Cancer. 2021;153:260-264.
Freeman D, Loe BS, Chadwick A, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (oceans) II. Psychol Med. 2020;1-15. https://doi.org/10.1017/S0033291720005188
Kosmidis PA, Lagogianni C, Kosmidis T. Multifactorial analysis of cancer patients’ willingness for COVID-19 vaccination. J Clin Oncol. 2021;39(15_suppl):12062-12062.
Australian Government Department of Health. Therapeutic Goods Administration. COVID-19 vaccine weekly safety report-12-08-2021. https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-12-08-2021. Accessed 25 August 2021.
Dwyer A, Marosits M, Weltzien E, et al. Landscape of COVID-19 vaccine uptake in the colorectal cancer community: responding to community needs. J Clin Oncol. 2021;39(15_suppl):e15577-e15577. Accessed 25 August 2021.
Victorian Comprehensive Cancer Care Alliance. Got cancer? Get vaccinated. https://www.viccompcancerctr.org/news/got-cancer-get-vaccinated. Accessed 25 August 2021.
Cancer Australia. COVID-19 information for people affected by cancer. Accessed August 2021. https://www.canceraustralia.gov.au/affected-cancer/information-about-cancer-and-covid-19/people-affected-cancer. Accessed 25 August 2021.
Ko T, Dendle C, Woolley I, et al. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. Hum Vaccin Immunother. 2021;1-9. https://doi.org/10.1080/21645515.2021.1958611

Auteurs

Mike Nguyen (M)

Oncology Department, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Nathan Bain (N)

Oncology Department, Monash Health, Clayton, Victoria, Australia.

Lisa Grech (L)

School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Tammie Choi (T)

Department of Nutrition, Dietetics and Food, Monash University, Clayton, Victoria, Australia.

Sam Harris (S)

Bendigo Health, Bendigo, Victoria, Australia.

Hieu Chau (H)

Latrobe Regional Hospital, Traralgon, Victoria, Australia.

Daniel Freeman (D)

Department of Psychiatry, University of Oxford, Oxford, UK.

Alastair Kwok (A)

Oncology Department, Monash Health, Clayton, Victoria, Australia.

Janne Williams (J)

Southern Melbourne Integrated Cancer Service, Melbourne, Victoria, Australia.

Amelia McCartney (A)

Oncology Department, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Kate Webber (K)

Oncology Department, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Daphne Day (D)

Oncology Department, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Eva Segelov (E)

Oncology Department, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH